Drugs that contain Imiquimod

1. List of Aldara drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7696159 BAUSCH Treatment for basal cell carcinoma
Apr, 2024

(1 year, 1 month from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696159

(Pediatric)

BAUSCH Treatment for basal cell carcinoma
Oct, 2024

(1 year, 7 months from now)

Market Authorisation Date: 27 February, 1997

Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines

Dosage: CREAM;TOPICAL

How can I launch a generic of ALDARA before it's patent expiration?
More Information on Dosage

2. List of Zyclara drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598196 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
Aug, 2029

(6 years from now)

US10238645 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Aug, 2029

(6 years from now)

US10238644 BAUSCH 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
Dec, 2029

(6 years from now)

US11318130 BAUSCH 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
Dec, 2029

(6 years from now)

US8236816 BAUSCH 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod
Dec, 2029

(6 years from now)

US8222270 BAUSCH 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod
Dec, 2029

(6 years from now)

US8299109 BAUSCH Method of treating actinic keratosis with 3.75% imiquimod cream
Dec, 2029

(6 years from now)

US10918635 BAUSCH Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
Apr, 2030

(7 years from now)

US11202752 BAUSCH Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
Apr, 2030

(7 years from now)

Market Authorisation Date: 25 March, 2010

Treatment: Treatment of genital warts; Treatment of perianal warts; Treatment of actinic keratosis

Dosage: CREAM;TOPICAL

How can I launch a generic of ZYCLARA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic